Wedbush Reiterates Neutral Rating, $5 PT on Sequenom on 4Q12 Revenues, EPS Loss
March 08, 2013 at 13:19 PM EST
In a report published Friday, Wedbush reiterated its Neutral rating and $5.00 price target on Sequenom (NASDAQ: SQNM ). Wedbush noted, “SQNM posted 4Q12 sales of $34 MM and a loss of ($0.29), which topped our revenue estimate of $33 MM and missed our EPS loss estimate of ($0.22). Results